← Leaderboards
David Feifel
University Of California San Diego
$6,058,485
Attributed
$6,058,485
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $637.5K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$6,058,485 · 6
By mechanism
R01$5,548,185 · 4
R34$510,300 · 1
M01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Neal R Swerdlow$20,712,760
- Zhigang David Luo$9,485,591
Others in their field
Top investigators on “Antipsychotic Agents”
- P Jeffrey Conn · Vanderbilt University$24,634,463
- Abraham Aizer Brody · New York University School Of Medicine$22,358,187
- Constantine G Lyketsos · Johns Hopkins University$14,554,427
- John H Krystal · Yale University$14,263,729
- Dilip V Jeste · University Of California San Diego$13,885,388
- Thomas Scott Stroup · University Of North Carolina Chapel Hill$12,935,020
Research focus
Antipsychotic AgentsSchizophreniaBaseCognitive DeficitsAnimal ModelTherapeutic EffectSiteAffinitySocialMediatingRattusBrainResearch StudyExhibitsShort-Term MemoryNeurotensinInterestCognitiveChronicSymptomsPeripheralDesignRattus NorvegicusFuture
Grant awards (29)
Oxytocin as a therapeutic target for Schizophrenia$357,500
R01 · FY2019 · MH · contact PI
Oxytocin as a therapeutic target for Schizophrenia$357,500
R01 · FY2018 · MH · contact PI
Oxytocin as a therapeutic target for Schizophrenia$252,850
R01 · FY2017 · MH · contact PI
Oxytocin as a therapeutic target for Schizophrenia$387,500
R01 · FY2016 · MH · contact PI
Oxytocin as a therapeutic target for Schizophrenia$382,275
R01 · FY2015 · MH · contact PI
Neurotensin-1 Receptor as a Therapeutic Target for Schizophrenia$367,092
R01 · FY2013 · MH · contact PI
Neurotensin-1 Receptor as a Therapeutic Target for Schizophrenia$382,388
R01 · FY2012 · MH · contact PI
1/2-Anti-Psychotic Effects of Oxytocin$255,150
R34 · FY2012 · MH · contact PI
Neurotensin-1 Receptor as a Therapeutic Target for Schizophrenia$382,388
R01 · FY2011 · MH · contact PI
1/2-Anti-Psychotic Effects of Oxytocin$255,150
R34 · FY2011 · MH · contact PI
Neurotensin-1 Receptor as a Therapeutic Target for Schizophrenia$386,250
R01 · FY2010 · MH · contact PI
Neurotensin-1 Receptor as a Therapeutic Target for Schizophrenia$383,389
R01 · FY2009 · MH · contact PI
A Novel Animal Model of Relevance to Schizophrenia$219,741
R01 · FY2009 · MH · contact PI
A Novel Animal Model of Relevance to Schizophrenia$219,741
R01 · FY2008 · MH · contact PI
A Novel Animal Model of Relevance to Schizophrenia$219,741
R01 · FY2007 · MH · contact PI
A Novel Animal Model of Relevance to Schizophrenia$226,304
R01 · FY2006 · MH · contact PI
A Novel Animal Model of Relevance to Schizophrenia$225,526
R01 · FY2005 · MH
Antipsychotic-Like Drug Effects of Neurotensin$266,000
R01 · FY2004 · MH
Antipsychotic-Like Drug Effects of Neurotensin$266,000
R01 · FY2003 · MH
Antipsychotic-Like Drug Effects of Neurotensin$266,000
R01 · FY2002 · MH
OLANZAPINE + DEVALPROEX VS PLACEBO + DEVALPROEX$0
M01 · FY2002 · RR
OLANZAPINE + DEVALPROEX VS PLACEBO + DEVALPROEX$0
M01 · FY2002 · RR
OLANZAPINE + DEVALPROEX VS PLACEBO + DEVALPROEX$0
M01 · FY2002 · RR
OLANZAPINE + DEVALPROEX VS PLACEBO + DEVALPROEX$0
M01 · FY2002 · RR
OLANZAPINE + DEVALPROEX VS PLACEBO + DEVALPROEX$0
M01 · FY2001 · RR
OLANZAPINE + DEVALPROEX VS PLACEBO + DEVALPROEX$0
M01 · FY2001 · RR
OLANZAPINE + DEVALPROEX VS PLACEBO + DEVALPROEX$0
M01 · FY2000 · RR
OLANZAPINE + DEVALPROEX VS PLACEBO + DEVALPROEX$0
M01 · FY2000 · RR
OLANZAPINE + DEVALPROEX VS PLACEBO + DEVALPROEX$0
M01 · FY2000 · RR